The primary analysis of the S1826S study will be presented on June 4 at the American Society of Clinical Oncology (ASCO) Annual Meeting. The randomized phase III SWOG study is evaluating nivolumab combined with doxorubicin, vinblastine, dacarbazine (AVD) chemotherapy versus brentuximab vedotin with AVD as initial treatment of advanced-stage classic Hodgkin lymphoma (cHL).
“The results from S1826 set the stage for a new standard of care for the treatment of advanced-stage cHL,” said Alex Herrera, MD, of City of Hope Medical Center in Duarte, California, who will present the findings at a plenary session. S1826 is the largest HL trial conducted in the North American cooperative groups (National Cancer Institute’s National Clinical Trials Network [NCTN]), led by the SWOG Cancer Research Network, Dr. Herrera added.
For decades, adult and pediatric approaches to the treatment of cHL have differed, with a majority of the very youngest patients with cHL who are vulnerable to late effects of treatment receiving radiotherapy, Dr. Herrera explained. As a collaboration between the adult cooperative groups and Children’s Oncology Group, the S1826 study is a “key step towards harmonizing the treatment of HL and has sparked ongoing NCTN collaboration in adolescent, young adult patients with lymphoma,” Dr. Herrera said.
Any conflicts of interest declared by the authors can be found in the original abstract.
Reference
Herrera A, LeBlanc M, Castellino S, et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). Chicago. Abstract LBA4. Presented at the ASCO Annual Meeting, June 4, 2023; Chicago, Illinois.
